A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

Study Summary

Primary Objectives: To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA Secondary Objective: To determine the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) profile of ferumoxytol in pediatric subjects.

Conditions

Chronic Kidney Disease; Iron Deficiency Anemia

Interventions / Drugs

Ferumoxytol Iron sucrose

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment129 participants

Primary Completion—

Lead SponsorAMAG Pharmaceuticals, Inc.

Data Retrieved2026-04-11 02:53:30.728000+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.